For the 7 months during 2016 that he was CEO of Valeant Pharmaceuticals, Joseph Papa was paid $62.7 million.

Papa started in May of last year. During his tenure in 2016, Valeant’s stock price fell 55%, the company lost $2.4 billion and revenue declined 7.4%.